Ischemic microvasculature and impaired angiogenesis

Ischemic microvasculature and impaired angiogenesis refers to a pathological state where the network of small blood vessels fails to provide adequate blood flow to tissues, and the body's natural ability to grow new vessels is compromised. This condition is a hallmark of chronic cardiovascular and metabolic diseases, such as diabetes and peripheral artery disease, where persistent hypoxia leads to tissue necrosis and impaired healing (Source: NIH, PMC3690378). The biological failure often involves the downregulation or resistance to pro-angiogenic factors like Vascular Endothelial Growth Factor (VEGF) and the dysfunction of the Hypoxia-Inducible Factor (HIF) pathway (Source: StatPearls, NBK532303). Therapeutic interventions, often termed 'therapeutic angiogenesis,' utilize growth factors, gene therapies, or small molecule stabilizers to bypass arterial blockages and restore microcirculatory function (Source: PubMed, PMID: 30135131). However, stimulating these pathways carries significant safety risks, including the potential to promote occult tumor growth or exacerbate diabetic retinopathy (Source: PMC, PMC4127684).

Other names

Impaired neovascularizationMicrovascular rarefactionDefective angiogenesisIschemic microangiopathyReduced capillary density

Therapeutic strategies aim to stimulate the formation of new blood vessels by activating pro-angiogenic signaling pathways, such as the VEGF/VEGFR axis or the HIF-1 alpha oxygen-sensing pathway, to restore perfusion and oxygen delivery to ischemic tissues (Source: PubMed, PMID: 25644361).